Active Biotech: Interim report January - March 2017
April 27, 2017 08:30 (CEST)RegulatoryLaquinimod
- The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
- The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
- The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
- Orphan Drug Designation granted for laquinimod for the treatment of Huntington's disease by the US Food and Drug Administration (FDA)
ANYARA
- Project proceeding according to plan
Tasquinimod, paquinimod and SILC
- Out-licensing activities are continuing
- The European Patent Office has granted a patent application covering tasquinimod for use in the treatment of multiple myeloma
- Orphan Drug Designation granted for tasquinimod for the treatment of multiple myeloma by the US Food and Drug Administration (FDA)
- Product patent for SILC substances granted by the European Patent Office
Financial summary
SEK M | Jan.-Mar. | Full-year | ||
2017 | 2016 | 2016 | ||
Net sales | 4.7 | 3.9 | 19.0 | |
Operating loss | -14.6 | -16.1 | -55.1 | |
Loss after tax | -15.8 | -16.8 | -59.6 | |
Loss per share, before and after dilution (SEK) | -0.16 | -0.19 | -0.65 | |
Cash and cash equivalents (at close of period) | 62.7 | 76.5 | 77.7 | |
- Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017
For further information, please contact:
Tomas Leanderson, President and CEO Tel: +46 (0) 46 19 20 95 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 |
The report is also available at www.activebiotech.com.